|
N- nitroso mebendazole
|
|
0
|
100
|
April 13, 2025
|
|
Clobam Nitrosamine Impurity
|
|
0
|
145
|
April 8, 2025
|
|
Risk mitigation based on DP specifications
|
|
10
|
695
|
April 7, 2025
|
|
:brazil: Lhasa Brazil Symposium: Aligning Pharma & Regulatory Standards Globally :brazil:
|
|
0
|
149
|
April 3, 2025
|
|
Evaluation of the nitrosamine impurities of ACE inhibitors using computational, in vitro, and in vivo methods demonstrate no genotoxic potential -Pub
|
|
8
|
590
|
April 2, 2025
|
|
Health Canada recalled drug products
|
|
0
|
783
|
April 1, 2025
|
|
Quantitative Investigation of Nitrosamine Drug Substance-Related Impurities (NDSRIs) Under Artificial Gastric Conditions by Liquid Chromatography–Tandem Mass Spectrometry and Structure–Activity Relationship Analysis -Pub
|
|
0
|
314
|
March 24, 2025
|
|
Chemistry of N-Nitroso Ivacaftor
|
|
10
|
1554
|
March 21, 2025
|
|
AI limits and CPCA score (O=NN1CCN=C1CCl)
|
|
8
|
444
|
March 17, 2025
|
|
Analytical procedure development and proposed established conditions: A case study of a mass spectrometry based NDSRI analytical procedure -Pub
|
|
20
|
2169
|
March 12, 2025
|
|
Is there any possibility to generate the N-Desmethyl Tramadol in formulation?
|
|
5
|
643
|
March 11, 2025
|
|
Nitrosamines et énantiomères
|
|
2
|
291
|
February 18, 2025
|
|
How to calculate the Limit of Nitrosamines from excipients?
|
|
5
|
852
|
February 4, 2025
|
|
What is CPCA Score for “N-nitroso of 3-Amino-1,2,4-triazole"
|
|
7
|
575
|
January 30, 2025
|
|
Risk Assessment and Management Strategy of Two New Nitrosamine Drug Substance Related Impurities (NDSRIs) in a Pharmaceutical Drug Product for the Treatment of a Rare Disease- from Prediction to Control-Pub
|
|
0
|
582
|
January 29, 2025
|
|
EMA nitrosamine Q&A Appendix 1 rev.7 published on Dec 13, 2024
|
|
8
|
2559
|
January 27, 2025
|
|
🛑 N-nitroso Ticagrelor
|
|
16
|
3574
|
January 23, 2025
|
|
FREE Lhasa Webinar | Nitrosaminas en el horizonte: ¿Está preparado? 🇲🇽
|
|
1
|
300
|
January 22, 2025
|
|
Control of N-nitrosamine impurities in drug products: Progressing the current CPCA framework and supporting the derivation of robust compound specific Acceptable Intakes-Pub
|
|
10
|
833
|
January 20, 2025
|
|
Acceptable Intake N-Nitrosobiotin (N-Nitrosamide)
|
|
2
|
336
|
January 13, 2025
|
|
SCIEX Webinar: Unlocking precision: nitrosamine and NDSRI analysis(16.1.2025 10:30 CET)
|
|
0
|
393
|
January 12, 2025
|
|
FDA Updates Recall on Blood Pressure Medication Due to Possible Carcinogen
|
|
3
|
1118
|
December 27, 2024
|
|
Limit of N-nitroso morpholine in Rocuronium Br
|
|
0
|
166
|
December 12, 2024
|
|
N-Nitroso Metoprolol
|
|
0
|
188
|
November 20, 2024
|
|
Hypothetical Nitrosamine in 1-H Indazole / CPCA Approach
|
|
3
|
183
|
October 31, 2024
|
|
📅 Analytical challenges and the effective management of nitrosamines: The evolving landscape of NDSRI analysis
|
|
3
|
650
|
October 30, 2024
|
|
N-Nitroso Desmethyl Tramadol
|
|
3
|
859
|
October 29, 2024
|
|
Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA) -Pub
|
|
0
|
312
|
October 29, 2024
|
|
Hexamethyldisilazane (HMDS) can form Nitrosamine Impurity?
|
|
7
|
610
|
October 29, 2024
|
|
N-Nitrosamine drug substance related impurities (NDSRIs) – A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 Da -Pub
|
|
0
|
321
|
October 28, 2024
|